CC-90010

DRUG4 trials

Sponsors

Celgene, Bristol-Myers Squibb

Conditions

Advanced Solid TumorsAstrocytomaGlioblastomaLymphoma, Non-HodgkinNeoplasms

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

TerminatedNCT03220347

CelgeneLymphoma, Non-Hodgkin, Neoplasms

Start: 2017-07-24End: 2024-09-06Updated: 2024-10-08

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

TerminatedNCT04047303

CelgeneAstrocytoma, Glioblastoma

Start: 2020-01-02End: 2024-06-03Updated: 2024-07-05

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

TerminatedNCT04324840

CelgeneGlioblastoma

Start: 2020-07-10End: 2024-07-09Updated: 2024-07-26

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

WithdrawnNCT05678283

Bristol-Myers SquibbAdvanced Solid Tumors

Start: 2023-01-09End: 2024-04-29Updated: 2024-04-17

Related Papers

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.

2023-03-1315 citations

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study

Neuro-Oncology2022-12-0129 citations

CTNI-21. TROTABRESIB (CC-90010) IN COMBINATION WITH CONCOMITANT TEMOZOLOMIDE PLUS RADIOTHERAPY AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: UPDATED RESULTS FROM A PHASE 1B/2 STUDY

Neuro-Oncology2022-11-01

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

Neuro-Oncology Advances2022-01-0117 citations

CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY

Neuro-Oncology2021-11-021 citations

CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A REVERSIBLE, POTENT ORAL BROMODOMAIN AND EXTRATERMINAL INHIBITOR (BETi) IN PATIENTS WITH HIGH-GRADE GLIOMAS: A PHASE 1 OPEN-LABEL ‘WINDOW OF OPPORTUNITY’ STUDY

Neuro-Oncology2021-11-02

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

2020-03-3049 citations

Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Journal of Clinical Oncology2019-05-20